Caroline Bouter1, Birgit Meller2, Carsten O Sahlmann2, Wieland Staab3, Hans J Wester4, Saskia Kropf5, Johannes Meller2. 1. Department of Nuclear Medicine, Georg-August-University Göttingen, Göttingen, Germany caroline.bouter@med.uni-goettingen.de. 2. Department of Nuclear Medicine, Georg-August-University Göttingen, Göttingen, Germany. 3. Department of Radiology, Georg-August-University Göttingen, Göttingen, Germany. 4. Pharmaceutical Radiochemistry, Technical University of Munich, Garching, Germany; and. 5. SCINTOMICS GmbH, Fuerstenfeldbruck, Germany.
Abstract
Because of its role in infection and inflammatory processes, the chemokine receptor CXCR4 might be a potent target in imaging of infectious and inflammatory diseases. The aim of this pilot study was to determine whether the CXCR4 ligand 68Ga-pentixafor is suitable for imaging chronic infection of the bone. Methods: The study comprised 14 patients with suspected infection of the skeleton who underwent 68Ga-pentixafor PET/CT between April 2015 and February 2017 in our facility. 68Ga-pentixafor PET/CT results were retrospectively evaluated against a histologic, bacteriologic, and clinical standard. The results were also compared with available bone scintigraphy, white blood cell scintigraphy, and 18F-FDG PET/CT results. Results: 68Ga-pentixafor PET/CT was positive in 9 of 14 patients. Diagnoses included osteitis or osteomyelitis of peripheral bone, osteomyelitis of the maxilla, and infected endoprostheses. Target-to-background ratios were 5.1-15 (mean, 8.7). Eight of 9 cases were true-positive as confirmed by pathology, bacteriology, or clinical observation. All negative cases were confirmed as true-negative by other imaging modalities and follow-up. Conclusion: Imaging of CXCR4 expression with 68Ga-pentixafor PET/CT appears suitable for diagnosing chronic infection of the skeleton. The findings of this study reveal a possible diagnostic gain in suspected chronic infections that are difficult to diagnose by other imaging modalities.
Because of its role in infection and inflammatory processes, the chemokine receptor CXCR4 might be a potent target in imaging of infectious and inflammatory diseases. The aim of this pilot study was to determine whether the CXCR4 ligand 68Ga-pentixafor is suitable for imaging chronic infection of the bone. Methods: The study comprised 14 patients with suspected infection of the skeleton who underwent 68Ga-pentixafor PET/CT between April 2015 and February 2017 in our facility. 68Ga-pentixafor PET/CT results were retrospectively evaluated against a histologic, bacteriologic, and clinical standard. The results were also compared with available bone scintigraphy, white blood cell scintigraphy, and 18F-FDG PET/CT results. Results: 68Ga-pentixafor PET/CT was positive in 9 of 14 patients. Diagnoses included osteitis or osteomyelitis of peripheral bone, osteomyelitis of the maxilla, and infected endoprostheses. Target-to-background ratios were 5.1-15 (mean, 8.7). Eight of 9 cases were true-positive as confirmed by pathology, bacteriology, or clinical observation. All negative cases were confirmed as true-negative by other imaging modalities and follow-up. Conclusion: Imaging of CXCR4 expression with 68Ga-pentixafor PET/CT appears suitable for diagnosing chronic infection of the skeleton. The findings of this study reveal a possible diagnostic gain in suspected chronic infections that are difficult to diagnose by other imaging modalities.
Authors: Filipa Mota; Alvaro A Ordonez; George Firth; Camilo A Ruiz-Bedoya; Michelle T Ma; Sanjay K Jain Journal: J Med Chem Date: 2020-02-21 Impact factor: 7.446
Authors: Andreas K Buck; Rudolf A Werner; Alessandro Lambertini; Philipp E Hartrampf; Takahiro Higuchi; Sebastian E Serfling; Patrick Meybohm; Andreas Schirbel Journal: Eur J Nucl Med Mol Imaging Date: 2022-08-12 Impact factor: 10.057
Authors: Rogerio B Craveiro; Alexandru Florea; Christian Niederau; Sihem Brenji; Fabian Kiessling; Sabri E M Sahnoun; Agnieszka Morgenroth; Felix M Mottaghy; Michael Wolf Journal: Cells Date: 2022-09-21 Impact factor: 7.666
Authors: Malte Kircher; Peter Herhaus; Margret Schottelius; Andreas K Buck; Rudolf A Werner; Hans-Jürgen Wester; Ulrich Keller; Constantin Lapa Journal: Ann Nucl Med Date: 2018-08-13 Impact factor: 2.668